TARP as antigen in cancer immunotherapy.
Cancer-associated antigen
Immunotherapy
TARP
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
16
03
2021
accepted:
17
05
2021
pubmed:
30
5
2021
medline:
16
10
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
In recent decades, immunotherapy has become a pivotal element in cancer treatment. A remaining challenge is the identification of cancer-associated antigens suitable as targets for immunotherapeutics with potent on-target and few off-tumor effects. The T-cell receptor gamma (TCRγ) chain alternate reading frame protein (TARP) was first discovered in the human prostate and androgen-sensitive prostate cancer. Thereafter, TARP was also identified in breast and endometrial cancers, salivary gland tumors, and pediatric and adult acute myeloid leukemia. Interestingly, TARP promotes tumor cell proliferation and migration, which is reflected in an association with worse survival. TARP expression in malignant cells, its role in oncogenesis, and its limited expression in normal tissues raised interest in its potential utility as a therapeutic target, and led to development of immunotherapeutic targeting strategies. In this review, we provide an overview of TARP expression, its role in different cancer types, and currently investigated TARP-directed immunotherapeutic options.
Identifiants
pubmed: 34050774
doi: 10.1007/s00262-021-02972-x
pii: 10.1007/s00262-021-02972-x
pmc: PMC8164403
doi:
Substances chimiques
Antigens, Neoplasm
0
Nuclear Proteins
0
TARP
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3061-3068Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Med Clin North Am. 2017 Nov;101(6):1053-1073
pubmed: 28992854
J Clin Oncol. 2018 Jul 20;36(21):2181-2189
pubmed: 29874137
Cancer Gene Ther. 2006 Jan 1;13(1):13-20
pubmed: 16052227
Front Immunol. 2019 Mar 28;10:603
pubmed: 30984182
Blood. 2003 Oct 1;102(7):2387-94
pubmed: 12816873
Front Oncol. 2019 Jul 10;9:626
pubmed: 31355143
Leukemia. 2015 Nov;29(11):2238-47
pubmed: 25987253
Oncogene. 2005 Jan 6;24(1):188-98
pubmed: 15637592
Cancer Immunol Immunother. 2018 Dec;67(12):1863-1869
pubmed: 29143114
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9437-42
pubmed: 10931945
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 2004 Jun 4;279(23):24561-8
pubmed: 15150260
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Oncoimmunology. 2016 Jul 01;5(8):e1197459
pubmed: 27622067
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Br J Haematol. 2018 Nov;183(3):512-516
pubmed: 29076143
Int J Hematol. 2017 May;105(5):549-557
pubmed: 28357569
J Vet Sci. 2012 Dec;13(4):345-53
pubmed: 23271175
Chin Med J (Engl). 2013 Nov;126(22):4260-4
pubmed: 24238509
Nat Rev Cancer. 2002 Dec;2(12):938-50
pubmed: 12459732
Nat Commun. 2016 Jun 13;7:11804
pubmed: 27292946
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Apr;123(4):468-476
pubmed: 28153567
Biochem Pharmacol. 2019 Oct;168:275-284
pubmed: 31323186
Pediatr Clin North Am. 2020 Dec;67(6):1237-1251
pubmed: 33131544
J Immunol. 2006 Sep 15;177(6):4187-95
pubmed: 16951384
Mol Cell Biol. 1990 Dec;10(12):6500-11
pubmed: 2247069
Blood. 2011 Apr 21;117(16):4262-72
pubmed: 21296998
Eur J Immunol. 2008 Jun;38(6):1706-20
pubmed: 18446790
Cancer Res. 2001 Nov 15;61(22):8122-6
pubmed: 11719440
Drug Des Devel Ther. 2018 Nov 12;12:3885-3898
pubmed: 30518999
Prostate. 2004 Oct 1;61(2):161-70
pubmed: 15305339
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9287-92
pubmed: 10430935
Haematologica. 2020 May;105(5):1306-1316
pubmed: 31371409
Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):300-4
pubmed: 9419370
Adv Exp Med Biol. 2017;1036:51-64
pubmed: 29275464
Genes Dev. 1994 Dec 1;8(23):2857-67
pubmed: 7995523
Endocrinology. 2003 Aug;144(8):3433-40
pubmed: 12865322
Mol Ther. 2004 Aug;10(2):355-64
pubmed: 15294182
BMC Immunol. 2016 Jul 13;17(1):23
pubmed: 27411667
Breast Cancer Res Treat. 2000 May;61(2):111-9
pubmed: 10942096
Cell Mol Immunol. 2015 Nov;12(6):656-68
pubmed: 25864915
Mol Biol Cell. 1994 Mar;5(3):339-47
pubmed: 8049525
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Blood. 2016 Sep 8;128(10):1396-407
pubmed: 27338099
Br J Cancer. 1999 Mar;79(9-10):1594-602
pubmed: 10188912
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Cancer Res. 2008 Mar 15;68(6):1988-96
pubmed: 18339881
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):6-11
pubmed: 19581923
Clin Cancer Res. 2005 May 15;11(10):3869-78
pubmed: 15897588
Hemasphere. 2020 Feb 26;4(2):e346
pubmed: 32309783
Cancer Res. 2004 Apr 1;64(7):2610-8
pubmed: 15059918
Cardiol Clin. 2019 Nov;37(4):533-544
pubmed: 31587793
Oncoimmunology. 2020 Feb 17;9(1):1727078
pubmed: 32117593
Trends Mol Med. 2010 Feb;16(2):77-87
pubmed: 20122868
Cancer Res. 2011 Mar 1;71(5):1805-15
pubmed: 21233334
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15877-81
pubmed: 23019373